Vaccinex calls warrants after positive Alzheimer's trial FDG-PET signal

VACCINEX, INC.

Warrants from Oct/Nov 2023, Feb/Mar 2024 financings called for cancellation at $0.0001/share.
Call triggered by statistically significant increase in FDG-PET signal in SIGNAL-AD pepinemab trial.
Warrant holders have 20 or 30 trading days to exercise; unexercised warrants auto-cancel.
Company plans to explore additional financing options, including warrant inducement or exchange.
No guarantee of warrant exercise or success of any potential financing transactions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.